Medicinova (MNOV)

Company Profile

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative cervical myelopathy (DCM), substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma (GBM), as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova's pipeline also includes MN-221 (bedoradrine) and MN-029 (denibulin).

Company profile

Ticker

MNOV

Exchange

NASDAQ

Website

www.medicinova.com

CEO

Yuichi Iwaki

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

SEC CIK

0001226616

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

MEDICINOVA JAPAN INC. • AVIGEN, INC • MEDICINOVA EUROPE GmbH ...

IRS number

330927979

MNOV stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

10-K/A

2022 FY

Annual report (amended)

28 Mar 23

16 Feb 23

10 Nov 22

Prospectus supplement for primary offering

30 Sep 22

EFFECT

Notice of effectiveness

7 Sep 22

CORRESP

Correspondence with SEC

11 Aug 22

Departure of Directors or Certain Officers

21 Jun 22

Latest ownership filings

View all

3D Investment Partners Pte. Ltd.

Financial summary

Financial statements Chart MNOV financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	18.51 mm	18.51 mm	18.51 mm	18.51 mm	18.51 mm	18.51 mm
Cash burn (monthly)	11.33 mm	4.41 mm	1.08 mm	1.22 mm	1.34 mm	1.08 mm
Cash used (since last report)	34.03 mm	13.24 mm	3.23 mm	3.66 mm	4.01 mm	3.23 mm
Cash remaining	-15.52 mm	5.27 mm	15.27 mm	14.85 mm	14.50 mm	15.28 mm
Runway (months of cash)	-1.4	1.2	14.2	12.2	10.9	14.2

Beta Read what these cash burn values mean

Financial data from Medicinova earnings reports.

Institutional ownership, Q4 2022

MNOV institutional ownership history Ownership history

27.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	42	34	+23.5%
Opened positions	12	1	+1100.0%
Closed positions	4	3	+33.3%
Increased positions	9	7	+28.6%
Reduced positions	12	15	-20.0%

13F shares	Current	Prev Q	Change
Total value	9.31 bn	28.79 mm	+32229.8%
Total shares	11.71 mm	12.20 mm	-4.0%
Total puts	0.00	0.00
Total calls	16.10 k	0.00	NEW
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
3D Investment Partners Pte.	5.50 mm	$14.25 mm	0.0%
Essex Woodlands Management	1.11 mm	$2.27 bn	0.0%
BLK Blackrock	711.78 k	$1.46 bn	+0.2%
Vanguard	625.83 k	$1.28 bn	-65.8%
C Citigroup	447.96 k	$918.31 mm	-0.5%
Geode Capital Management	437.25 k	$896.00 k	+1.0%
Jane Street	267.82 k	$549.04 mm	NEW
Millennium Management	251.63 k	$516.00 k	-28.7%
JPM JPMorgan Chase & Co.	249.35 k	$511.00 k	-16.3%
Bridgeway Capital Management	195.15 k	$400.05 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Vanguard	625.83 k	-1.20 mm	-65.8%
Jane Street	267.82 k	+267.82 k	NEW
HRT Financial	179.20 k	+179.20 k	NEW
STT State Street	142.30 k	+142.30 k	NEW
Ergoteles	111.00 k	+111.00 k	NEW
Millennium Management	251.63 k	-101.33 k	-28.7%
Capricorn Fund Managers	66.72 k	+66.72 k	NEW
GS Goldman Sachs	51.02 k	+51.02 k	NEW
Susquehanna International	64.36 k	-48.76 k	-43.1%
JPM JPMorgan Chase & Co.	249.35 k	-48.73 k	-16.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

MNOV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
23 Jan 23	Matsuda Kazuko	Employee Stock Option Common Stock	Grant	Acquire A	No	No	2.25	149,625	336.66 k	149,625
23 Jan 23	Geoffrey OBrien	Employee Stock Option Common Stock	Grant	Acquire A	No	No	2.25	76,950	173.14 k	76,950
23 Jan 23	Iwaki Yuichi	Employee Stock Option Common Stock	Grant	Acquire A	No	No	2.25	235,125	529.03 k	235,125
28 Nov 22	Nagao Hideki	Common Stock	Sell	Dispose S	No	No	2.25	6,754	15.20 k	0
22 Nov 22	Nagao Hideki	Common Stock	Sell	Dispose S	No	No	2.13	218	464.34	6,754
21 Nov 22	Nagao Hideki	Common Stock	Sell	Dispose S	No	No	2.18	5,365	11.70 k	6,972